Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study. (ChromoKey)
An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.
Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC.
Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup.
These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
ChromoKey is a prospective, open-label, multicenter, two-cohort, non-randomized phase 2 study evaluating the efficacy and safety of first-line lenvatinib plus pembrolizumab (Cohort A) and later-line lenvatinib plus everolimus (Cohort B) in patients with metastatic chromophobe renal cell carcinoma (chRCC).
The study enrolls 40 patients across two independent cohorts, with 20 patients in each cohort. Eligible patients are adults with histologically confirmed metastatic chRCC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients from all International Metastatic RCC Database Consortium (IMDC) risk groups are eligible.
Cohort A includes patients who have received no previous systemic therapy for metastatic disease. Patients receive lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks.
Cohort B includes patients whose disease progresses following previous systemic therapy and who have not previously received lenvatinib. Patients receive lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily. Treatment continues until disease progression or unacceptable toxicity.
The primary endpoint is the objective response rate in each cohort, defined as the proportion of patients achieving a complete or partial response according to RECIST version 1.1.
Secondary endpoints include progression-free survival, overall survival, duration of response, and safety. Tumor response is evaluated using radiological assessments, and safety is assessed through monitoring of adverse events, clinical examinations, and laboratory investigations.
Each cohort is evaluated independently to characterize the activity and tolerability of the respective combination in its treatment setting. The study does not include randomization or a formal comparison between the two cohorts.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Ilya Tsimafeyeu
- Phone Number: +74999054690
- Email: bucare@bucare.org
Study Locations
-
-
-
Chelyabinsk, Russia
- Recruiting
- Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
-
Contact:
- Natalia Glushankova
- Phone Number: +74999054690
- Email: sten_to@mail.ru
-
Krasnoyarsk, Russia
- Recruiting
- V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
-
Contact:
- Ruslan Zukov
- Phone Number: +74999054690
- Email: sten_to@mail.ru
-
Orenburg, Russia
- Recruiting
- Orenburg Regional Cancer Center
-
Contact:
- Makhabbat Murzalina
- Phone Number: +74999054690
- Email: sten_to@mail.ru
-
Saint Petersburg, Russia
- Recruiting
- Dr. Berezin Medical Institute
-
Contact:
- Grigory Raskin
- Phone Number: +74999054690
- Email: sten_to@mail.ru
-
Saint Petersburg, Russia
- Recruiting
- SBHI Leningrad regional clinical hospital, Saint-Petersburg
-
Contact:
- Andrei Lebedinets
- Phone Number: +74999054690
- Email: sten_to@mail.ru
-
Saratov, Russia
- Recruiting
- Saratov Regional Cancer Center
-
Contact:
- Svetlana Averianova
- Phone Number: +74999054690
- Email: sten_to@mail.ru
-
Ufa, Russia
- Recruiting
- Republican Clinical Oncology Dispensary
-
Contact:
- Alexander Sultanbaev
- Phone Number: +74999054690
- Email: sten_to@mail.ru
-
Yekaterinburg, Russia
- Recruiting
- Sverdlovskiy Regional Oncological Dispensary
-
Contact:
- Marina Zafirova
- Phone Number: +74999054690
- Email: sten_to@mail.ru
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed chromophobe renal cell carcinoma.
- Measurable disease according to RECIST version 1.1.
- ECOG performance status of 0-3.
- Cohort A: No prior systemic therapy for metastatic disease.
- Cohort B: Disease progression following prior systemic therapy and no previous exposure to lenvatinib
- Adequate bone marrow, hepatic, and renal function.
- Signed informed consent.
Exclusion Criteria:
- Uncontrolled or symptomatic central nervous system metastases or leptomeningeal disease.
- Uncontrolled hypertension despite appropriate antihypertensive treatment.
- Clinically significant uncontrolled cardiovascular disease.
- Active infection requiring systemic treatment.
- Active clinically significant bleeding or a high risk of severe hemorrhage.
- Major surgery without adequate postoperative recovery or a serious non-healing wound.
- Gastrointestinal conditions that significantly impair the absorption of oral study medications.
- Known severe hypersensitivity to any component of the assigned study treatment.
- Current pneumonitis or interstitial lung disease.
- Pregnancy or breastfeeding.
- Any medical or psychiatric condition that, in the investigator's judgment, compromises patient safety or adherence to study procedures.
- Cohort A only: Active autoimmune disease requiring systemic immunosuppressive treatment, or a requirement for chronic systemic immunosuppression, excluding physiological corticosteroid replacement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort A: first-line lenvatinib plus pembrolizumab
lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks |
tablets solution |
|
Experimental: Cohort B: later-line lenvatinib plus everolimus
lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily |
tablets tablets |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response rate
Time Frame: 12 months
|
the proportion of patients achieving a complete or partial response according to RECIST version 1.1 |
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
progression-free survival
Time Frame: 24 months
|
the time from treatment initiation to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. |
24 months
|
|
overall survival
Time Frame: 24 months
|
the time from treatment initiation to death from any cause |
24 months
|
|
duration of response
Time Frame: 24 months
|
the time from the first documented complete or partial response to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first |
24 months
|
|
Grade 3 and higher treatment-emergent adverse events
Time Frame: 24 months
|
the proportion of patients experiencing at least one treatment-emergent adverse event of grade 3 or higher according to NCI CTCAE version 5.0. |
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Urologic Neoplasms
- Carcinoma
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Organic Chemicals
- Macrolides
- Lactones
- Sirolimus
- Everolimus
- lenvatinib
Other Study ID Numbers
Other Study ID Numbers
- ChromoKey
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study results are disseminated through scientific publications and conference presentations in aggregate form.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.